Research programme: second generation zebularine molecules - Idogen

Drug Profile

Research programme: second generation zebularine molecules - Idogen

Latest Information Update: 29 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Idogen; Lund University
  • Developer Idogen; Lund University; University of Oxford
  • Class Antineoplastics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus; Rheumatoid arthritis

Most Recent Events

  • 23 Mar 2017 Idogen has a patent pending for its zebularine molecules technology in the US
  • 05 Dec 2016 Idogen has patent protection for additional aspects of using zebularine for the treatment of autoimmune diseases and rejection of transplanted organs in Europe
  • 20 Jul 2016 Preclinical trials in Rheumatoid arthritis in Sweden (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top